ClickCease 2013 | Page 6 of 7 | Walkup, Melodia, Kelly & Schoenberger

Study: Wrongful Death More Common In Rural Hospitals

A study recently published in the Journal of the American Medical Association finds that the wrongful death rate among rural hospitals increased during the past decade while death rates at urban hospitals have fallen. So-called “critical access hospitals” are medical facilities that provide inpatient care to Californians living in rural communities. Researchers say that these…

Read More

Walkup Melodia, Kelly & Schoenberger Obtains $8.3 million Verdict against Johnson & Johnson in first DePuy metal-on-metal hip trial

The San Francisco Law Firm of Walkup, Melodia, Kelly & Schoenberger has obtained a $8.3 million verdict against Johnson & Johnson in the first DePuy hip implant trial. The product liability attorneys at Walkup successfully demonstrated that the metal-on-metal design of DePuy’s hip implants was defective and caused patient harm. DePuy’s Hip Implants: Anatomy Of…

Read More

MUNI accident fatality rates remain consistent, MTA says

The number of fatal MUNI accidents has remained consistent for two years, according to a recent report by the San Francisco Municipal Transportation Agency (SFMTA). Fatal bus and rail accidents peaked in 2007-2008, but have remained relatively unchanged since then. San Francisco’s Municipal Railway is part of the nation’s seventh-largest transit system. MUNI connects commuters…

Read More

San Francisco car accident injuries on the rise

San Francisco’s streets were slightly more dangerous last year, the San Francisco Municipal Transportation Agency (SFMTA) says. The city saw 3,111 nonfatal injury traffic accidents in 2011, 30 more than the prior year. The number of fatal traffic collisions also increased from 23 in 2010 to 28 in 2011. A variety of factors can contribute…

Read More

Amgen to pay $762M for marketing deadly drug to cancer patients

Drugmaker Amgen recently agreed to a $762 million settlement of criminal penalties and whistleblower lawsuits related to its illegal marketing of Aranesp, an anemia drug. Federal prosecutors say that the drugmaker marketed its pharmaceuticals for uses that the U.S. Food and Drug Administration (FDA) explicitly ruled out. “Promoting drugs for unapproved purposes is beyond wrong;…

Read More